Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT00543387 2024-06-05

MK-5108-001

Phase 1 Completed

35 enrolled 15 charts

Tumor-Agnostic

Neoplasms

NCT01920061 2022-09-13

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Phase 1 Completed

110 enrolled 80 charts

Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT01362374 2022-01-12

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

Phase 1 Completed

122 enrolled

Tumor-Agnostic

Neoplasms

NCT03057366 2019-11-18

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Phase 1 Completed

8 enrolled 26 charts

Tumor-Agnostic

Neoplasms

NCT00848718 2019-11-12

MK-2206-003

Phase 1 Completed

77 enrolled 24 charts

Tumor-Agnostic

Neoplasms

NCT01868022 2019-08-19

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Phase 1 Completed

65 enrolled 32 charts

Tumor-Agnostic

Neoplasms

NCT00704821 2019-05-10

PTC299 for Treatment of Advanced Cancer

Phase 1 Terminated

76 enrolled

Tumor-Agnostic

Neoplasms

NCT00148902 2017-12-06

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

Phase 1 Completed

52 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT00201812 2017-12-06

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

27 enrolled

Tumor-Agnostic

Neoplasms

NCT01472016 2017-11-21

Study of ABT-700 in Subjects With Advanced Solid Tumors

Phase 1 Completed

74 enrolled

Tumor-Agnostic

Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1 Completed

169 enrolled

Tumor-Agnostic

Neoplasms

NCT01837667 2017-01-24

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Phase 1 Completed

29 enrolled

Tumor-Agnostic

Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Phase 1 Terminated

104 enrolled

Tumor-Agnostic

Neoplasms

NCT00705874 2016-07-21

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed

172 enrolled 13 charts

Lymphoid

Lymphoma, Neoplasms

NCT00487786 2016-01-18

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Phase 1 Completed

64 enrolled

Tumor-Agnostic

Neoplasms

NCT01685489 2015-10-27

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

Phase 1 Withdrawn

Genitourinary

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT01611961 2014-09-30

Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients

Phase 1 Unknown

35 enrolled

Tumor-Agnostic

Neoplasms

NCT02171676 2014-06-24

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

40 enrolled

Tumor-Agnostic

Neoplasms

NCT02171741 2014-06-24

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

31 enrolled

Tumor-Agnostic

Neoplasms

NCT00183742 2014-05-22

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

Phase 1 Completed

35 enrolled

Tumor-Agnostic

Carcinoma, Neoplasms

NCT00399087 2014-02-13

Phase I Trial of Docetaxel With Perifosine

Phase 1 Completed

39 enrolled

Tumor-Agnostic

Neoplasms

NCT00808418 2014-02-03

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

Phase 1 Completed

34 enrolled

Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00545246 2013-10-16

A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients

Phase 1 Completed

12 enrolled

Tumor-Agnostic

Neoplasms

NCT01095302 2013-10-16

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Phase 1 Completed

11 enrolled

Tumor-Agnostic

Neoplasms

NCT00322400 2013-07-31

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

Phase 1 Completed

46 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01604863 2012-11-01

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

Phase 1 Suspended

54 enrolled

GenitourinaryOther solid neoplasmThoracic

Lung Neoplasms, Mesothelioma, Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT01204996 2012-05-30

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

Phase 1 Completed

53 enrolled

Tumor-Agnostic

Neoplasms

NCT00454649 2012-04-04

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Phase 1 Completed

102 enrolled 48 charts

Tumor-Agnostic

Neoplasms

NCT00125411 2012-03-26

Study of Satraplatin (JM-216) in Combination With Docetaxel

Phase 1 Terminated

28 enrolled

Tumor-Agnostic

Neoplasms

NCT00606814 2012-03-06

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

60 enrolled

Tumor-Agnostic

Neoplasms

NCT01148615 2012-01-13

A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

Phase 1 Completed

20 enrolled

Tumor-Agnostic

Neoplasms

NCT00390676 2010-12-28

A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine

Phase 1 Completed

Tumor-Agnostic

Neoplasms

NCT00049296 2010-06-11

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Phase 1 Completed

26 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckLymphoidOther hematologic neoplasmPlasma cellSarcomaThoracic

AIDS-related Kaposi sarcoma, Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Appendiceal Neoplasms, Astrocytoma, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Chondrosarcoma, Colonic Neoplasms, Craniopharyngioma, Ependymoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glioblastoma, Glioma, Carcinoma, Hepatocellular, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Meningioma, Multiple Myeloma, Neoplasms, Neuroblastoma, Oligodendroglioma, Pancreatic Neoplasms, Pinealoma, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Stomach Neoplasms, Urethral Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive, Esthesioneuroblastoma, Olfactory, Glioma, Subependymal, Gliosarcoma, Lymphoma, B-Cell, Marginal Zone, Breast Neoplasms, Male, Lymphoma, Mantle-Cell, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Small Cell Lung Carcinoma

NCT00193570 2009-01-23

Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors

Phase 1 Completed

20 enrolled

Tumor-Agnostic

Neoplasms